Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.

Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.

Enzomenib might be the most promising agent so far, on a cross-trial basis.